Literature DB >> 15561835

Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.

Mayumi Matsuoka1, Mitsuo Narita, Norio Okazaki, Hitomi Ohya, Tsutomu Yamazaki, Kazunobu Ouchi, Isao Suzuki, Tomoaki Andoh, Tsuyoshi Kenri, Yuko Sasaki, Atsuko Horino, Miharu Shintani, Yoshichika Arakawa, Tsuguo Sasaki.   

Abstract

In recent years, Mycoplasma pneumoniae strains that are clinically resistant to macrolide antibiotics have occasionally been encountered in Japan. Of 76 strains of M. pneumoniae isolated in three different areas in Japan during 2000 to 2003, 13 strains were erythromycin (ERY) resistant. Of these 13 strains, 12 were highly ERY resistant (MIC, > or =256 microg/ml) and 1 was weakly resistant (MIC, 8 microg/ml). Nucleotide sequencing of domains II and V of 23S rRNA and ribosomal proteins L4 and L22, which are associated with ERY resistance, showed that 10 strains had an A-to-G transition at position 2063 (corresponding to 2058 in Escherichia coli numbering), 1 strain showed A-to-C transversion at position 2063, 1 strain showed an A-to-G transition at position 2064, and the weakly ERY-resistant strain showed C-to-G transversion at position 2617 (corresponding to 2611 in E. coli numbering) of domain V. Domain II and ribosomal proteins L4 and L22 were not involved in the ERY resistance of these clinical M. pneumoniae strains. In addition, by using our established restriction fragment length polymorphism technique to detect point mutations of PCR products for domain V of the 23S rRNA gene of M. pneumoniae, we found that 23 (24%) of 94 PCR-positive oral samples taken from children with respiratory infections showed A2063G mutation. These results suggest that ERY-resistant M. pneumoniae infection is not unusual in Japan.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561835      PMCID: PMC529214          DOI: 10.1128/AAC.48.12.4624-4630.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.

Authors:  N Okazaki; M Narita; S Yamada; K Izumikawa; M Umetsu; T Kenri; Y Sasaki; Y Arakawa; T Sasaki
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

3.  Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides.

Authors:  O Y Misyurina; E V Chipitsyna; Y P Finashutina; V N Lazarev; T A Akopian; A M Savicheva; V M Govorun
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

4.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA.

Authors:  S T Gregory; A E Dahlberg
Journal:  J Mol Biol       Date:  1999-06-18       Impact factor: 5.469

6.  Mechanisms of bacterial resistance to macrolide antibiotics.

Authors:  Yoshinori Nakajima
Journal:  J Infect Chemother       Date:  1999-06       Impact factor: 2.211

7.  Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.

Authors:  T Ichiyama; M Nishikawa; T Yoshitomi; S Hasegawa; T Matsubara; T Hayashi; S Furukawa
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action.

Authors:  H Takizawa; M Desaki; T Ohtoshi; T Kikutani; H Okazaki; M Sato; N Akiyama; S Shoji; K Hiramatsu; K Ito
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

10.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  87 in total

1.  Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.

Authors:  Fei Zhao; Min Lv; Xiaoxia Tao; Hui Huang; Binghua Zhang; Zhen Zhang; Jianzhong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

4.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuguo Sasaki; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

6.  Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.

Authors:  Satowa Suzuki; Tsutomu Yamazaki; Mitsuo Narita; Norio Okazaki; Isao Suzuki; Tomoaki Andoh; Mayumi Matsuoka; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae.

Authors:  S Dégrange; C Cazanave; A Charron; H Renaudin; C Bébéar; C M Bébéar
Journal:  J Clin Microbiol       Date:  2009-02-09       Impact factor: 5.948

Review 8.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

Review 9.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

10.  Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.